
PLRX Stock Forecast & Price Target
PLRX Analyst Ratings
Bulls say
Pliant Therapeutics is given a HOLD rating by the financial analyst due to the lack of strong clinical data for their lead product candidate PLN-101095. The updated cash position and share counts have led to a decrease in the 12-month price target from $4 to $3 per share. Despite this, the company has a strong cash position of $192.4M that is expected to fund operations well into the second half of 2028.
Bears say
Pliant Therapeutics is experiencing strong preliminary results for their product PLN-101095, showing favorable response rates in a heavily pretreated patient population and inducing large increases in IFN-γ. However, the company's Ph1b trial design based on key findings from their Ph1 may lead to limited indication expansion. Additionally, there is a lack of data on the safety and efficacy in a larger patient population.
This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
PLRX Analyst Forecast & Price Prediction
Start investing in PLRX
Order type
Buy in
Order amount
Est. shares
0 shares